Based on the Abcellera Biologics Inc stock forecast from 2 analysts, the average analyst target price for Abcellera Biologics Inc is USD 8.67 over the next 12 months. Abcellera Biologics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Abcellera Biologics Inc is Neutral, which is based on 6 positive signals and 6 negative signals. At the last closing, Abcellera Biologics Inc’s stock price was USD 2.57. Abcellera Biologics Inc’s stock price has changed by +6.20% over the past week, +8.90% over the past month and -31.65% over the last year.
No recent analyst target price found for Abcellera Biologics Inc
No recent average analyst rating found for Abcellera Biologics Inc
Company Overview Abcellera Biologics Inc
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada. Read Less
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine ...Read More
Frequently Asked Questions About Abcellera Biologics Inc (ABCL) Stock
Based on ratings from 2 analysts Abcellera Biologics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on ABCL's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for ABCL is USD 8.67 over the next 12 months. The maximum analyst target price is USD 12 while the minimum anlayst target price is USD 4.
ABCL stock's Price/Earning ratio is 12.33.
Our analysis grades ABCL stock's Price / Earning ratio at F. This means that ABCL stock's Price/Earning ratio is above 62% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ABCL may be a overvalued for its sector.
The last closing price of ABCL's stock was USD 2.57.
The most recent market capitalization for ABCL is USD 0.69B.
Based on targets from 2 analysts, the average taret price for ABCL is projected at USD 8.67 over the next 12 months.
This means that ABCL's stock price may go up by +237.22% over the next 12 months.
We can't find any ETFs which contains Abcellera Biologics Inc's stock.
As per our most recent records Abcellera Biologics Inc has 596 Employees.
Abcellera Biologics Inc's registered address is 150 West 4th Ave, Vancouver, BC, Canada, V5Y 1G6.
You can get more information about it from Abcellera Biologics Inc's website at https://www.abcellera.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Abcellera Biologics Inc (ABCL) Stock
Based on ratings from 2 analysts Abcellera Biologics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on ABCL's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for ABCL is USD 8.67 over the next 12 months. The maximum analyst target price is USD 12 while the minimum anlayst target price is USD 4.
ABCL stock's Price/Earning ratio is 12.33.
Our analysis grades ABCL stock's Price / Earning ratio at F. This means that ABCL stock's Price/Earning ratio is above 62% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ABCL may be a overvalued for its sector.
The last closing price of ABCL's stock was USD 2.57.
The most recent market capitalization for ABCL is USD 0.69B.
Based on targets from 2 analysts, the average taret price for ABCL is projected at USD 8.67 over the next 12 months.
This means that ABCL's stock price may go up by +237.22% over the next 12 months.
We can't find any ETFs which contains Abcellera Biologics Inc's stock.
As per our most recent records Abcellera Biologics Inc has 596 Employees.
Abcellera Biologics Inc's registered address is 150 West 4th Ave, Vancouver, BC, Canada, V5Y 1G6.
You can get more information about it from Abcellera Biologics Inc's website at https://www.abcellera.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ABCL !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
